1. Home
  2. UFI vs TCRX Comparison

UFI vs TCRX Comparison

Compare UFI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unifi Inc. New

UFI

Unifi Inc. New

HOLD

Current Price

$4.00

Market Cap

74.3M

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.96

Market Cap

64.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFI
TCRX
Founded
1969
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.3M
64.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
UFI
TCRX
Price
$4.00
$0.96
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.50
AVG Volume (30 Days)
43.8K
468.7K
Earning Date
02-03-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$542,134,000.00
$8,423,000.00
Revenue This Year
$1.39
$286.83
Revenue Next Year
$12.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.96
$0.88
52 Week High
$6.03
$2.57

Technical Indicators

Market Signals
Indicator
UFI
TCRX
Relative Strength Index (RSI) 59.49 38.60
Support Level $3.96 $0.91
Resistance Level $4.20 $1.04
Average True Range (ATR) 0.19 0.07
MACD 0.00 -0.01
Stochastic Oscillator 48.48 15.43

Price Performance

Historical Comparison
UFI
TCRX

About UFI Unifi Inc. New

Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: